| Oct 28 |
Voyager Therapeutics (VYGR) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
|
| Oct 24 |
Kymera Therapeutics, Inc. (KYMR) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
|
| Oct 24 |
Kymera Therapeutics Announces Dosing of First Participant in Phase 1 Clinical Trial of KT-621, a First-in-Class Oral STAT6 Degrader, for the Treatment of TH2 Immuno-Inflammatory Diseases
|
| Oct 23 |
Kymera Therapeutics to Report Third Quarter 2024 Financial Results on October 31
|
| Oct 23 |
Kymera Therapeutics Announces Three Scientific Presentations at the EORTC-NCI-AACR 2024 Symposium
|
| Oct 10 |
Kymera's IND Application for STAT6 Degrader Gets FDA Clearance
|
| Oct 9 |
Kymera gets FDA clearance for Phase 1 testing of KT-621
|
| Oct 9 |
Kymera Therapeutics Announces FDA Clearance of Investigational New Drug Application for KT-621, a First-in-Class, Oral STAT6 Degrader
|
| Oct 6 |
Kymera's Protein Degradation Technology: A Promising Bet For Long-Term Biotech Investors
|
| Sep 25 |
Kymera Therapeutics Presents Preclinical Data for KT-621, a Potent, Selective, First-In-Class, Oral STAT6 Degrader at the EADV Congress
|
